IPP Bureau
Lundbeck’s bocunebart shows breakthrough potential in migraine prevention
By IPP Bureau - February 16, 2026
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
BridgeBio reports breakthrough results in Phase 3 achondroplasia trial
By IPP Bureau - February 16, 2026
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
Lyell Immunopharma launches groundbreaking Phase 3 CAR T-Cell trial for aggressive lymphoma
By IPP Bureau - February 16, 2026
PiNACLE is a head-to-head study comparing its next-generation CAR T-cell therapy against established therapies liso-cel and axi-cel in patients with relapsed or refractory large B-cell lymphoma
Centivax launches first human trial of universal flu vaccine
By IPP Bureau - February 16, 2026
Agilent’s PD-L1 test gains FDA nod for ovarian cancer
By IPP Bureau - February 16, 2026
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
NATCO receives CDSCO approval for Semaglutide in India
By IPP Bureau - February 15, 2026
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
Zydus receives final approval from USFDA for Ammonium Lactate Cream, 12%
By IPP Bureau - February 15, 2026
Akums surges in Q3 FY26 with 15% revenue jump, bags key EU & UK nods
By IPP Bureau - February 14, 2026
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
FDA nod to Acrotech's new eczema treatment
By IPP Bureau - February 14, 2026
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
Fortis Healthcare posts strong Q3 FY26 growth; revenues up 17.5% YoY
By IPP Bureau - February 14, 2026
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
FDA refuses to file Moderna’s seasonal flu vaccine application, citing comparator issue
By IPP Bureau - February 14, 2026
The FDA’s Center for Biologics Evaluation and Research (CBER) cited Moderna’s choice of a licensed standard-dose flu vaccine as the comparator in its Phase 3 trial, saying it “does not reflect the best-available standard of care.”
Citius Oncology expands LYMPHIR access across Europe via exclusive Uniphar deal
By IPP Bureau - February 14, 2026
Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories
Precision BioSciences cleared by FDA to launch groundbreaking Duchenne gene editing trial
By IPP Bureau - February 14, 2026
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
BioAsia 2026 positions Telangana as a global TechBio powerhouse
By IPP Bureau - February 14, 2026
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
